BR112017011891A2 - métodos de prevenção, redução ou tratamento de degeneração macular - Google Patents

métodos de prevenção, redução ou tratamento de degeneração macular

Info

Publication number
BR112017011891A2
BR112017011891A2 BR112017011891A BR112017011891A BR112017011891A2 BR 112017011891 A2 BR112017011891 A2 BR 112017011891A2 BR 112017011891 A BR112017011891 A BR 112017011891A BR 112017011891 A BR112017011891 A BR 112017011891A BR 112017011891 A2 BR112017011891 A2 BR 112017011891A2
Authority
BR
Brazil
Prior art keywords
prevention
reduction
treatment
methods
macular degeneration
Prior art date
Application number
BR112017011891A
Other languages
English (en)
Inventor
K Mcvicar William
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of BR112017011891A2 publication Critical patent/BR112017011891A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112017011891A 2014-12-03 2015-12-02 métodos de prevenção, redução ou tratamento de degeneração macular BR112017011891A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087080P 2014-12-03 2014-12-03
PCT/US2015/063450 WO2016090005A1 (en) 2014-12-03 2015-12-02 Methods of preventing, reducing or treating macular degeneration

Publications (1)

Publication Number Publication Date
BR112017011891A2 true BR112017011891A2 (pt) 2018-07-03

Family

ID=56092394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011891A BR112017011891A2 (pt) 2014-12-03 2015-12-02 métodos de prevenção, redução ou tratamento de degeneração macular

Country Status (12)

Country Link
US (1) US20160158267A1 (pt)
EP (1) EP3247715A1 (pt)
JP (1) JP2018501219A (pt)
KR (1) KR20170123605A (pt)
CN (1) CN107406479A (pt)
AU (1) AU2015358576A1 (pt)
BR (1) BR112017011891A2 (pt)
CA (1) CA2967446A1 (pt)
EA (1) EA201790851A1 (pt)
IL (1) IL252394A0 (pt)
MX (1) MX2017007318A (pt)
WO (1) WO2016090005A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4353315A3 (en) * 2018-11-14 2024-05-15 Smilebiotek Zhuhai Limited Animal models, screening methods, and treatment methods for intraocular diseases or disorders
DK3886852T3 (da) * 2018-12-03 2024-04-29 Smilebiotek Zhuhai Ltd Octylgallat og estere deraf til anvendelse ved behandling og forebyggelse af aldersrelateret makuladegeneration forårsaget af bacillus megaterium
CN111658740B (zh) * 2020-06-19 2021-09-14 南京中医药大学 具有改善年龄相关性黄斑变性的药食两用组合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321460A (zh) * 2005-11-30 2008-12-10 伊诺泰克制药公司 嘌呤衍生物及其用法
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
BRPI1009971A2 (pt) * 2009-05-01 2016-03-15 Inoteck Pharmaceuticals Corp método de redução da pressão intraocular em humanos
KR20120091049A (ko) * 2009-10-26 2012-08-17 이노텍 파마슈티컬스 코포레이션 안과용 제제 및 이의 제조 방법
EP2523669B1 (en) * 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
PT2555775T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e inibidores de anidrase carbónica para redução da pressão intra-ocular
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
AU2011230618A1 (en) * 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
AU2011230580A1 (en) * 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
CA2833806A1 (en) * 2011-04-28 2012-11-01 Claire Mitchell Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
MX2015013234A (es) * 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
US20140275128A1 (en) * 2013-03-15 2014-09-18 Inotek Pharmaceuticals Corporation Method of providing ocular neuroprotection

Also Published As

Publication number Publication date
WO2016090005A1 (en) 2016-06-09
KR20170123605A (ko) 2017-11-08
US20160158267A1 (en) 2016-06-09
JP2018501219A (ja) 2018-01-18
MX2017007318A (es) 2017-08-25
AU2015358576A1 (en) 2017-06-22
EA201790851A1 (ru) 2017-11-30
CA2967446A1 (en) 2016-06-09
IL252394A0 (en) 2017-07-31
CN107406479A (zh) 2017-11-28
EP3247715A1 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
HK1246179A1 (zh) 治療視網膜疾病的方法
GB201701673D0 (en) Methods of well treatment
EP3122414A4 (en) Venous disease treatment
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
IL250513A0 (en) Treatment of episode disorders
EP3234116A4 (en) Methods of treating tissue calcification
PT3233071T (pt) Método de tratamento ou prevenção de doenças mediadas por ras
GB201410116D0 (en) Method of treatment
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
BR112018000204A2 (pt) métodos de tratamento de colite
IL253028A0 (en) treatment method
IL251769A0 (en) Methods for treating eye conditions
EP3134108A4 (en) Agents and methods of treatment
GB201416832D0 (en) Methods of treatment
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
IL252394A0 (en) Methods for preventing, reducing or treating macular degeneration
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
BR112016028196A2 (pt) método de inibição ou tratamento de fibrose
AU2015905220A0 (en) Methods of treatment
GB2532447B (en) Treatment of Contaminated Land
EP3139924A4 (en) Methods of treating or preventing preterm labor
EP3188744A4 (en) Methods for treatment and prevention of vascular disease
AU2015902366A0 (en) Treatment for myopia
AU2014902334A0 (en) Treatment for myopia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]